Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Colorcon
Dow
Moodys

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

QBRELIS Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Qbrelis patents expire, and what generic alternatives are available?

Qbrelis is a drug marketed by Silvergate Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in QBRELIS is lisinopril. There are twenty-one drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

US ANDA Litigation and Generic Entry Outlook for Qbrelis

A generic version of QBRELIS was approved as lisinopril by CASI PHARMS INC on July 1st, 2002.

  Start Trial

Drug patent expirations by year for QBRELIS
Drug Prices for QBRELIS

See drug prices for QBRELIS

Recent Clinical Trials for QBRELIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Jude Children's Research HospitalPhase 2
National Cancer Institute (NCI)Phase 2
Mayo ClinicPhase 2

See all QBRELIS clinical trials

Pharmacology for QBRELIS
Paragraph IV (Patent) Challenges for QBRELIS
Tradename Dosage Ingredient NDA Submissiondate
QBRELIS SOLUTION;ORAL lisinopril 208401 2019-10-24

US Patents and Regulatory Information for QBRELIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Colorcon
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.